Evaluation of Clinical Effectiveness of Semaglutide Combined with Insulin Degludec in the Treatment of Overweight or Obese Type 2 Diabetes Mellitus
Objective To investigate the effectiveness of overweight or obese type 2 diabetes mellitus patients treated with a combination of semaglutide and insulin degludec.Methods 80 patients of overweight or obese type 2 diabetes mellitus admitted to Jingjiang People's Hospital Affiliated to Yangzhou University from June 2022 to October 2023 were randomly selected as the study objects.According to random number table method,they were divided into two groups with 40 cases in each group.The control group was treated with insulin degludec+metformin,and the observa-tion group was treated with insulin degludec+metformin+semaglutide.Clinical efficacy,glycemic indexes,islet func-tion and body mass index(BMI),and adverse reactions were compared.Results The total effective rate of treatment in the observation group was 97.50%,higher than 80.00% in the control group,the difference was statistically signifi-cant(χ2=6.134,P=0.013).There was no statistically significant difference in blood glucose index,islet function in-dex,and BMI of the two groups before treatment(all P>0.05).After treatment,those in the observation group were better than those in the control group,the differences were statistically significant(all P<0.05).There was no statisti-cally significant difference in adverse reactions between the two groups(P>0.05).Conclusion For overweight or obese patients with type 2 diabetes mellitus,a combination drug regimen of semaglutide and insulin degludec can be taken on the basis of metformin to promote the improvement of pancreatic islet function and reduce the level of blood glucose indexes and BMI,and the combination of drugs is safe.
Overweight or obese type 2 diabetes mellitusSemaglutideInsulin degludecBlood glucose indexPancreatic islet function
NETL
NSTL
万方数据
